Janux Therapeutics’ (JANX) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

Several other brokerages have also recently issued reports on JANX. Stifel Nicolaus began coverage on Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. UBS Group initiated coverage on Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. Scotiabank cut their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $66.44.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX opened at $48.76 on Thursday. Janux Therapeutics has a one year low of $7.79 and a one year high of $65.60. The firm has a market capitalization of $2.56 billion, a P/E ratio of -41.67 and a beta of 3.52. The company’s fifty day moving average is $49.76 and its two-hundred day moving average is $46.30.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, sell-side analysts forecast that Janux Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares in the company, valued at approximately $132,839,742. The trade was a 3.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the business’s stock in a transaction on Friday, October 18th. The shares were bought at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the purchase, the director now owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This trade represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 420,610 shares of company stock valued at $19,288,666 over the last 90 days. Insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC acquired a new position in shares of Janux Therapeutics in the 1st quarter valued at about $251,000. Lord Abbett & CO. LLC acquired a new position in Janux Therapeutics during the first quarter valued at approximately $20,420,000. Vanguard Group Inc. grew its stake in Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after buying an additional 378,477 shares during the period. StemPoint Capital LP acquired a new stake in shares of Janux Therapeutics in the first quarter worth $4,580,000. Finally, Altitude Crest Partners Inc. purchased a new position in shares of Janux Therapeutics in the 1st quarter valued at $7,278,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.